Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States

CONCLUSIONS: The 90-day TFV ring was well-tolerated, acceptable and exceeded target cervical tissue concentrations through day 56, but declined thereafter. Additional studies are needed to characterize the higher release from TFV rings in some participants and the optimal duration of use.PMID:38444118 | DOI:10.1002/jia2.26223

Source: Journal of the International AIDS Society - March 6, 2024 Category: Infectious Diseases Authors: Albert Y Liu Holly Gundacker Barbra Richardson Beatrice A Chen Craig Hoesley Ariane van der Straten Amanda Brown May Beamer Jennifer Robinson Cindy E Jacobson Rachel Scheckter Katherine Bunge Jill Schwartz Andrea Thurman Jeanna M Piper Mark A Marzinke MTN Source Type: research